Sitagliptin: Anti-platelet effect in diabetes and healthy volunteers

References

• Jackson WS, Nesbitt S, Kulkarni J. Signaling events underlying thrombus formation. J Thromb Haemost 2003; 1: 1602–1612
   PubMed Web of Science ®Google Scholar
• Croce K, Flaumenhaft R, Rivers M, Furie B, Furie BC, Herman IM, Potter DA. Inhibition of calpain blocks platelet secretion, aggregation, and spreading. J Biol Chem 1999; 274: 36321–36327
   PubMed Web of Science ®Google Scholar
• Harper AGS, Mason MJ, Sage SO. A key role of dense granule secretion in potentiation of the Ca2+ signal arising from store- operated calcium entry in human platelets. Cell Calcium 2009; 45: 413–420
   PubMed Web of Science ®Google Scholar
• Barkalow KL, Falet H, Itliano JE, Jr, Vugt AV, Christopher CL, Schreiber AD, Hartwig JH. Role for phosphoinositide 3-kinase in Fcγ RII A induced platelet shape change. Am J Physiol Cell Physiol 2003; 285: C797–C805
   Web of Science ®Google Scholar
• del Castillo A, Vitale M, Trifaro JM. Ca2+ and pH determine the interaction of chromaffin cell scinderin with phosphatidyl serine 4, 5-biphosphate and its cellular distribution during nicotinic-receptor stimulation and protein kinase-C activation. J Cell Biol 1992; 119: 797–810
   PubMed Web of Science ®Google Scholar
• Fox JEB. The platelet cytoskeleton. Thromb Haemost 1993; 70: 884–893
   PubMed Web of Science ®Google Scholar
• Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis 1998; 137: S65–S73
   PubMed Web of Science ®Google Scholar
• Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner BA. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151: 1141–1147
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type-2 diabetes. N Engl J Med 2003; 348: 383–393
   PubMed Web of Science ®Google Scholar
• Reaven PD, Moritz TE, Schwenke DC, Anderson RJ, Criqui M, Detrano R, Emanuele N, Kayshap M, Marks J, Mudaliar S, et al. Intensive glucose lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes 2009; 58: 2642–2648
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Athyros VG, Adamidou F, Panagiotou A, Kita M, Karagiannis A, Mikhailidis DP. Glucagon- like peptide-1-based therapies and cardiovascular disease: Looking beyond glycemic control. Diabetes Obes Metab 2011; 13: 302–312
   PubMed Web of Science ®Google Scholar
• Drucker D, Easley C, Kirkpatric P. Sitagliptin. Nat Rev Drug Discov 2007; 6: 109–110
   PubMed Web of Science ®Google Scholar
• Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type-2 diabetes. Horm Metab Res 2004; 36: 867–876
   PubMed Web of Science ®Google Scholar
• Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in Patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91(11)4612–4619
   PubMed Web of Science ®Google Scholar
• Dicembrini H, Pala L, Rotella CM, From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitor therapy. Exper Diabetes Res 2011; article ID 898913:8
   Google Scholar
• Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, et al. 2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48: 141–151
   PubMed Web of Science ®Google Scholar
• Sachiko Hattori. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J 2011; 58(1)69–73
   PubMed Web of Science ®Google Scholar
• de Valk HW. DPP-4 inhibitors and combined treatment in type 2 diabetes: Re-evaluation of clinical success and safety. Rev Diabet Stud 2007; 4: 126–133
   PubMedGoogle Scholar
• Lamont BJ, Drucker DJ. Differential antidiabetic efficacy of incretin agonist versus dpp-4 inhibition in high fat–fed mice. Diabetes 2008; 57: 190–198
   PubMed Web of Science ®Google Scholar
• Tahara A, Yokono AM, Nakano R, Someya Y, Hayakawa M, Shibasaki M. Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: Comparison with other dipeptidyl peptidase-IV inhibitors. Pharmacol Rep 2009; 61: 899–908
   PubMed Web of Science ®Google Scholar
• Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008; 48(5): 592–598
   Web of Science ®Google Scholar
• Dicker D. DPP-4 inhibitors- Impact on glycemic control and cardiovascular risk factors. Diabetes Care 2011; 34: S276–S278
   PubMed Web of Science ®Google Scholar
• Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440–3450
   PubMed Web of Science ®Google Scholar
• Kakouros N, Rade JJ, Kourliouros A, Resar JR. Platelet function in patients with diabetes mellitus: From a theoretical to a practical perspective. Int J Endocrinol 2011; 2011: 742719
   PubMed Web of Science ®Google Scholar
• Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelets function in type II diabetes mellitus. N Eng J Med 1990; 322: 1769–1774
   PubMed Web of Science ®Google Scholar
• Ferreira MAD, Nunes ODRH, Fujimura AHY, Pessoa PLD, Lemos TLG, Viana GSB. Inhibition of platelet activation by quinones isolated from Auxemma oncocalyx Taub. Res Commun Mol Pathol Pharmacol 1999; 106: 97–107
   PubMedGoogle Scholar
• Ferreira MAD, do Nascimento NRF, de Sousa CM, Pessoa ODL, de Lemos TLG, Ventura JS, Schattner M, Chudzinski-Tavassi AM. Oncocalyxone-A inhibits human platelet aggregation by increasing cGMP and by binding to GP lbα glycoprotein. Br J Pharmacol 2008; 154(6)1216–1224
   PubMed Web of Science ®Google Scholar
• Mellion BT, Ignarro JL, Ohlstein EH, Pontecorvo EG, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3′-5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilatators. Blood 1981; 57: 946–955
   PubMed Web of Science ®Google Scholar
• Spies CD, Spies KP, Zinke S, Runkel N, Berger G, Marks C, Helling K, Blum S, Müller C, Rommelspacher H, et al. Alcoholism and carcinoma change the intracellular pH and activate platelet Na+/H+ exchange in men. Alcohol Clin Exp Res 1997; 21(9)1653–1660
   PubMed Web of Science ®Google Scholar
• Buitrago L, Langdon WY, Sanjay A, Kunapuli SP. Tyrosine phosphorylated c-Cbl regulates platelet functional responses mediated by outside-in signaling. Blood 2011; 118(20)5631–5640
   PubMed Web of Science ®Google Scholar
• Lagrue AH, Francischetti IM, Guimaraes JA, Jandrot-Perrus M. Phosphatidylinositol 3‘-kinase and tyrosine-phosphatase activation positively modulate Convulxin-induced platelet activation. Comparison with collagen. FEBS Lett 1999; 448(1)95–100
   PubMed Web of Science ®Google Scholar
• Jin YR, Im JH, Park ES, Cho MR, Han XH, Lee JJ, Lim Y, Kim TJ, Yun YP. Antiplatelet activity of epigallocatechin gallate is mediated by the inhibition of PLCgamma2 phosphorylation, elevation of PGD2 production, and maintaining calcium-ATPase activity. J Cardiovasc Pharmacol 2008; 51(1)45–54
   PubMed Web of Science ®Google Scholar
• Blankenship KA, Dawson CB, Aronoff GR, Dean WL. Tyrosine phosphorylation of human platelet plasma membrane Ca2+– ATPase in hypertension. Hypertension 2000; 35: 103–107
   PubMed Web of Science ®Google Scholar
• Touyz RM, Schiffrin EL. Effects of angiotensin II and endothelin-1 on platelet aggregation and cytosolic pH and free Ca2+ concentrations in essential hypertension. Hypertension 1993; 22(6)853–862
   PubMed Web of Science ®Google Scholar
• Erne P, Bolli P, Burgisser E, Buhler FR. Correlation of platelet calcium with blood pressure: Effect of anti-hypertensive therapy. N Engl J Med 1984; 301: 1084–1088
   Google Scholar
• Resnick LM, Gupta RK, Sosa E, Corbett ML. Intracellular pH in human and experimental hypertension. Proc Natl Acad Sci USA 1987; 84: 7663–7667
   PubMed Web of Science ®Google Scholar
• Winocour PH. Drug therapy for prevention of cardiovascular disease – should surrogate measures is abandoned?. Clin Med 2005; 5(3)282–286
   PubMed Web of Science ®Google Scholar
• Arazi HC, Badimon JJ, Anti-Inflammatory effects of Anti-Platelet treatment in atherosclerosis. Curr Pharm Des 2012; PubMed PMID: 22236116 [Epub ahead of print]
   Google Scholar
• Primos G. Platelet aggregation inhibition with glycoprotein IIb-IIIb inhibitors. J Thromb Thrombolysis 2001; 11: 99–110
   PubMed Web of Science ®Google Scholar
• Kurrelmeyer K, Becker L, Becker D, Yanek L, Goldschmidt-Clermont P, Bray PF. Platelet hyperreactivity in women from families with premature atherosclerosis. J Am Med Womens Assoc 2003; 58(4)272–277
   Google Scholar